<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445055</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2006/02</org_study_id>
    <nct_id>NCT00445055</nct_id>
  </id_info>
  <brief_title>Evaluation of 2 Doses of Intravenous Droperidol in the Prevention of Postoperative Nausea</brief_title>
  <acronym>DIPAVO</acronym>
  <official_title>Study of Evaluation of the Profile of Efficiency / Tolerance of 2 Doses of Intravenous Droperidol in the Prevention of the Postoperative Nausea and Vomits Related to the Surgery of the Thyroid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prostrakan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective, randomised, placebo-controlled study, the researchers determined whether
      0.625 mg or 2.5 mg of IV droperidol given 30 min before emergence from general anaesthesia
      reduces the incidence of immediate and delayed post operative nausea and vomiting (PONV) in
      thyroid surgical female population. Two hundred and forty six female patients receiving
      general anaesthesia for thyroid surgery received either droperidol 0.625 mg or droperidol 2.5
      mg or placebo before emergence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Principal Objective : Our study examined one main question: Are there difference in
           efficacy between droperidol IV 0.625 mg or 2.5 mg for the treatment or prophylaxis of
           PONV to surgical patient undergoing thyroid surgery when they receive it 30 min before
           emergence from general anaesthesia?

        -  Secondary Objective :

             -  comparison of the % of patients in every group:

                  -  having a complete control of their nausea

                  -  requiring secondarily the appeal to another anti-emetic treatment in
                     postoperative

                  -  presenting an Adverse event

             -  Compare score of sedation in ach groups

             -  Evaluate electrocardiograph

             -  Compare the morphine consumption

        -  Study design : Prospective, randomized, monocenter, double-blind study

        -  Inclusion criteria :

             -  Female

             -  More than 18 years old

             -  Patients scheduled for thyroid surgery

             -  Simplified Apfel score ≥ 2

             -  ASA score : 1-2

             -  Informed consent obtained from the patient

             -  the women in age of procreate must have a reliable contraceptive method

        -  Exclusion criteria :

             -  age &lt; 18 years old

             -  male

             -  obesity

             -  present a severe depressive syndrome

             -  pregnancy women

             -  trouble of cardiac rate

             -  alcoholism

             -  contra-indication for Droperidol prescription

        -  Study plan: three parallel groups will receive 2 different doses of Droperidol or
           placebo at the end of surgery.

             -  Group 1: 0,625mg of Droperidol at the end of surgery

             -  Group 2: 2,5mg of Droperidol at the end of surgery

             -  Group 3: Placebo at the end of surgery

        -  Number of subjects : 246
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No vomiting episode</measure>
    <time_frame>During the first four hours after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Light nausea</measure>
    <time_frame>24h post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of nausea</measure>
    <time_frame>24h post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-vomiting treatment</measure>
    <time_frame>24h post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>24h post operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modification of electrocardiograph</measure>
    <time_frame>30 min and 120 min after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Score of sedation</measure>
    <time_frame>24h post operative</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous injection of 0,625 mg Droperidol, 30 min before the end of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous injection of 2,5 mg Droperidol, 30 min before the end of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous injection of NaCl 9% (Placebo), 30 min before the end of anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Droperidol</intervention_name>
    <description>Intravenous injection</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  More than 18 years old

          -  Patients scheduled for thyroid surgery

          -  Simplified Apfel score ≥ 2

          -  ASA score : 1-2

          -  Informed consent obtained from the patient

          -  Women able to procreate must have a reliable contraceptive method

        Exclusion Criteria:

          -  Age &lt; 18 years old

          -  Male

          -  Obesity

          -  Has a severe depressive syndrome

          -  Pregnancy women

          -  Trouble with cardiac rate

          -  Alcoholism

          -  Contra-indication for Droperidol prescription
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gérard JANVIER, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laure BAUDOUIN, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Département d'Anesthésie-Réanimation II ; Groupe Hospitalier Sud, CHU de Bordeaux</name>
      <address>
        <city>PESSAC Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs. 2000 Feb;59(2):213-43. Review.</citation>
    <PMID>10730546</PMID>
  </reference>
  <reference>
    <citation>Williams OA, Clarke FL, Harris RW, Smith P, Peacock JE. Addition of droperidol to patient-controlled analgesia: effect on nausea and vomiting. Anaesthesia. 1993 Oct;48(10):881-4.</citation>
    <PMID>8031342</PMID>
  </reference>
  <reference>
    <citation>Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, Kovac A, Philip BK, Sessler DI, Temo J, Tramèr MR, Watcha M; Department of Anesthesiology, Duke University Medical Center. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg. 2003 Jul;97(1):62-71, table of contents. Review.</citation>
    <PMID>12818945</PMID>
  </reference>
  <reference>
    <citation>Wang JJ, Ho ST, Lee SC, Liu YC, Liu YH, Liao YC. The prophylactic effect of dexamethasone on postoperative nausea and vomiting in women undergoing thyroidectomy: a comparison of droperidol with saline. Anesth Analg. 1999 Jul;89(1):200-3.</citation>
    <PMID>10389804</PMID>
  </reference>
  <reference>
    <citation>Henzi I, Sonderegger J, Tramèr MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anaesth. 2000 Jun;47(6):537-51. Review.</citation>
    <PMID>10875717</PMID>
  </reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2007</study_first_posted>
  <last_update_submitted>December 12, 2011</last_update_submitted>
  <last_update_submitted_qc>December 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thyroidectomy</keyword>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <keyword>Droperidol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Droperidol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

